First, we found that NF-κB activation was markedly increased in DNR-treated B-ALL cells and NF-κB activation inhibitor can decrease Cyr61 production, suggesting that NF-κB signaling pathway is involved in DNR-induced Cyr61 production in B-ALL cells. The gene discussed is NFKB1; the disease is precursor B-cell acute lymphoblastic leukemia.